Literature DB >> 30125339

Reanalysis of exome sequencing data of intellectual disability samples: Yields and benefits.

Maryam Al-Nabhani1, Samiya Al-Rashdi1, Fathiya Al-Murshedi1,2, Adila Al-Kindi1,2, Khalid Al-Thihli1,2, Abeer Al-Saegh1,2, Amna Al-Futaisi3, Watfa Al-Mamari2,3, Fahad Zadjali4, Almundher Al-Maawali1,2.   

Abstract

Recently, with the advancement in next generation sequencing (NGS) along with the improvement of bioinformatics tools, whole exome sequencing (WES) has become the most efficient diagnostic test for patients with intellectual disability (ID). This study aims to estimate the yield of a reanalysis of ID negative exome cases after data reannotation. Total of 50 data files of exome sequencing, representing 50 samples were collected. The inclusion criteria include ID phenotype, and previous analysis indicated a negative result (no abnormality detected). These files were pre-processed and reannotated using ANNOVAR tool. Prioritized variants in the 50 cases studied were classified into three groups, (1) disease-causative variants (2) possible disease-causing variants and (3) variants in novel genes. Reanalysis resulted in the identification of pathogenic/likely pathogenic variants in six cases (12%). Thirteen cases (26%) were classified as having possible disease-causing variants. Candidate genes requiring future functional studies were detected in seven cases (14%). Improvement in bioinformatics tools, update in the genetic databases and literature, and patients' clinical phenotype update were the main reasons for identification of these variants in this study.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DNAH14; DRG1; ID; LIN7B; RIC3; SYCL2; diagnostic yield; variant interpretation; whole-exome sequencing

Mesh:

Year:  2018        PMID: 30125339     DOI: 10.1111/cge.13438

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  17 in total

1.  Unique bioinformatic approach and comprehensive reanalysis improve diagnostic yield of clinical exomes.

Authors:  Klaus Schmitz-Abe; Qifei Li; Samantha M Rosen; Neeharika Nori; Jill A Madden; Casie A Genetti; Monica H Wojcik; Sadhana Ponnaluri; Cynthia S Gubbels; Jonathan D Picker; Anne H O'Donnell-Luria; Timothy W Yu; Olaf Bodamer; Catherine A Brownstein; Alan H Beggs; Pankaj B Agrawal
Journal:  Eur J Hum Genet       Date:  2019-04-12       Impact factor: 4.246

Review 2.  The clinical utility of exome and genome sequencing across clinical indications: a systematic review.

Authors:  Salma Shickh; Chloe Mighton; Elizabeth Uleryk; Petros Pechlivanoglou; Yvonne Bombard
Journal:  Hum Genet       Date:  2021-08-08       Impact factor: 4.132

3.  The Responsibility to Recontact Research Participants after Reinterpretation of Genetic and Genomic Research Results.

Authors:  Yvonne Bombard; Kyle B Brothers; Sara Fitzgerald-Butt; Nanibaa' A Garrison; Leila Jamal; Cynthia A James; Gail P Jarvik; Jennifer B McCormick; Tanya N Nelson; Kelly E Ormond; Heidi L Rehm; Julie Richer; Emmanuelle Souzeau; Jason L Vassy; Jennifer K Wagner; Howard P Levy
Journal:  Am J Hum Genet       Date:  2019-04-04       Impact factor: 11.025

4.  Increasing African genomic data generation and sharing to resolve rare and undiagnosed diseases in Africa: a call-to-action by the H3Africa rare diseases working group.

Authors:  Aimé Lumaka; Nadia Carstens; Koenraad Devriendt; Amanda Krause; Benard Kulohoma; Judit Kumuthini; Gerrye Mubungu; John Mukisa; Melissa Nel; Timothy O Olanrewaju; Zané Lombard; Guida Landouré
Journal:  Orphanet J Rare Dis       Date:  2022-06-16       Impact factor: 4.303

5.  Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets.

Authors:  Catherine G Fischer; Aparna Pallavajjala; LiQun Jiang; Valsamo Anagnostou; Jessica Tao; Emily Adams; James R Eshleman; Christopher D Gocke; Ming-Tseh Lin; Elizabeth A Platz; Rena R Xian
Journal:  Clin Cancer Res       Date:  2022-06-01       Impact factor: 13.801

6.  A three-year follow-up study evaluating clinical utility of exome sequencing and diagnostic potential of reanalysis.

Authors:  Jasmine L F Fung; Mullin H C Yu; Shushu Huang; Claudia C Y Chung; Marcus C Y Chan; Sander Pajusalu; Christopher C Y Mak; Vivian C C Hui; Mandy H Y Tsang; Kit San Yeung; Monkol Lek; Brian H Y Chung
Journal:  NPJ Genom Med       Date:  2020-09-10       Impact factor: 8.617

Review 7.  Diagnosing rare diseases after the exome.

Authors:  Laure Frésard; Stephen B Montgomery
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-12-17

8.  Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders.

Authors:  Siddharth Srivastava; Jamie A Love-Nichols; Kira A Dies; David H Ledbetter; Christa L Martin; Wendy K Chung; Helen V Firth; Thomas Frazier; Robin L Hansen; Lisa Prock; Han Brunner; Ny Hoang; Stephen W Scherer; Mustafa Sahin; David T Miller
Journal:  Genet Med       Date:  2019-06-11       Impact factor: 8.822

9.  Re-analysis of whole-exome sequencing data uncovers novel diagnostic variants and improves molecular diagnostic yields for sudden death and idiopathic diseases.

Authors:  Elias L Salfati; Emily G Spencer; Sarah E Topol; Evan D Muse; Manuel Rueda; Jonathan R Lucas; Glenn N Wagner; Steven Campman; Eric J Topol; Ali Torkamani
Journal:  Genome Med       Date:  2019-12-17       Impact factor: 11.117

Review 10.  Genetic Counseling in Neurodevelopmental Disorders.

Authors:  Alyssa Blesson; Julie S Cohen
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.